Iryna PIROZHKOVA
Publications
Publications
MBD-Seq was applied to study the CpG methylation map of immortallyzed human myoblasts after DiPRO1/ZNF555 inhibition. BioStudies, E-MTAB-136892024 |
|
ZNF555 interaction partners in human rhabdomyosarcoma cells. ProteomeXchange, PRIDE PXD0275422024 |
|
UCSC browser public track: DiPRO1/ZNF555 differentially methylated CpG islands using the Methylated-CpG island recovery assay sequencing (MIRA-seq).2023 |
|
Inhibition and overexpression of DiPRO1/ZNF555 distinctly modulates the transcriptome of human myoblasts, rhabdomyosarcoma and Ewing sarcoma cells2022 |
|
MBD-Seq was applied to study the CpG methylation map of rhabdomyosarcoma cells after DiPRO1/ZNF555 inhibition. BioStudies, E-MTAB-108252022 |
|
|
Nuclei reprogramming during muscle denervationAt the crossroads of cellular plasticity, reproduction and microbiology, Apr 2024, Dourdan, France |
|
|
Muscle wasting in head and neck carcinomas: Investigations on the underlying transcriptional reprogrammationAACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, Apr 2021, Philadelphia, United States. pp.2656-2656, ⟨10.1158/1538-7445.AM2021-2656⟩ |
|
|
Role of DiPRO1 in mesenchymal cell fateFrom cell to organism: When cell biology meets development, Oct 2024, Paris, France. 2024 |
|
|
MUSCLE WASTING IN HEAD AND NECK CARCINOMAS: INVESTIGATIONS ON THE UNDERLYING TRANSCRIPTIONAL REPROGRAMMATIONAACR Annual Meeting 2021, Apr 2021, Philadelphie, United States |
|
|
Une nouvelle cible thérapeutique dans les cancers mésenchymateux pédiatriques2024 |
Therapeutic methods, products and compositions inhibiting ZNF555France, Patent n° : US10954515B2. 2021 |
|
THERAPEUTIC METHODS, PRODUCTS AND COMPOSITIONS INHIBITING ZNF555France, Patent n° : WO2016170022. 2016 |
Chromosome Conformation Capture (from 3C to 5C) and Its ChIP-Based ModificationChromatin Immunoprecipitation Assays, 567, Humana Press, pp.171-188, 2009, Methods in Molecular Biology, ⟨10.1007/978-1-60327-414-2_12⟩ |